Mankind Pharma has entered into an exclusive partnership with Innovent Biologics to license and commercialize Sintilimab, an immunotherapy for cancer treatment, in India.
The strategic collaboration aims to tackle major challenges in cancer care and improve patient access to innovative therapeutic options.
A Promising Cancer Treatment
Sintilimab, known as TYVYT (sintilimab injectable) in China, was developed through a collaboration between Eli Lilly and Innovent.
Currently, the drug has not been approved in India.
However, Mankind Pharma plans to seek regulatory approval for Sintilimab in 2025. The company intends to complete the necessary regulatory processes, including conducting a Phase III study in India.
The study will begin once Mankind Pharma receives regulatory clearance to proceed with such clinical trials.
Acquisition of Bharat Serums and Vaccines
In July 2024, Mankind Pharma also signed a definitive agreement to acquire Bharat Serums and Vaccines (BSV) from private equity firm Advent International.
The enterprise value of the transaction is approximately Rs136.3 billion.
Founded in 1971, Bharat Serums operates a research and development center in Mumbai, India, with a team of over 100 scientists.
The company has a strong global presence with subsidiaries in Germany, the Philippines, and the United States. It operates in more than 70 countries.
Mankind’s Exclusive Rights in India
Under the new agreement with Innovent Biologics, Mankind Pharma will hold the exclusive rights to register and import Sintilimab in India. The company will also have the rights to market, sell, and distribute the drug.
Innovent will be responsible for the manufacturing and supply of the product, ensuring that it remains available and meets the highest quality standards.
Innovent’s Commitment to Patient Care
Samuel Zhang, the Chief Business Officer at Innovent Biologics, emphasized the company’s commitment to improving patient care in India. He highlighted the goal of making advanced treatments like Sintilimab more accessible and affordable.
As reported by msn.com, the partnership marks a significant step forward in expanding treatment options for cancer patients in India. It offers hope for better outcomes and an improved quality of life.
